Written by James Walker
Published on Vol 6 Issue 1, 2026
Well-differentiated papillary thyroid carcinoma (PTC) is generally tied to an exceptionally good outlook; nonetheless, a handful of pathological traits—most notably macroscopic extrathyroidal extension and tumor size reaching or exceeding 2 cm—have been linked with structural reappearance of disease. The present study aimed to determine which clinical and histopathological features most strongly predict disease-free survival in patients undergoing total thyroidectomy for PTC. A retrospective rev
Written by Chen Hao
Published on Vol 6 Issue 1, 2026
This investigation delivers a 5-year review, looking backward, at the provision of genetic counseling (GC) focused on hereditary cancer syndromes (HCS) within a single Bulgarian center. The intention was to map the demographic and epidemiological contours of attendees, gauge willingness to proceed to genetic testing, and catalog the array of disease-linked mutations detected. The trends point toward progressively greater engagement with GC. Prominent observations include divergent characteristic
Written by Maria Silva
Published on Vol 6 Issue 1, 2026
A notable fraction of breast cancer occurrences stems from hereditary pathogenic mutations. Germline genetic testing (GGT), especially focused on BRCA1 and BRCA2, is an indispensable component of precision oncology, enabling tailored risk classification and the formulation of individualized treatment plans. Within this report, we investigate the practicality of performing blanket testing on all freshly diagnosed breast cancer patients, without regard for age, personal or familial cancer backgrou
Written by Ali Hassan
Published on Vol 6 Issue 1, 2026
To assess how thulium laser en bloc resection of bladder tumor (ERBT) compares with conventional transurethral resection of bladder tumor (TURBT) regarding their influence on catheter-related bladder discomfort (CRBD) in individuals with bladder cancer. From January 2022 through December 2024, we retrospectively collected demographic and clinical information from patients with bladder cancer. The study included 79 patients who underwent conventional TURBT and 58 who received thulium laser ERBT.
Written by Andreas Müller
Published on Vol 6 Issue 1, 2026
Using a case-control design, this investigation explored non-genetic determinants of colorectal cancer (CRC) among individuals in South Sulawesi. The participant pool comprised 89 cases and 84 controls, spanning ages 19 to 86, with 99 men and 74 women from multiple ethnicities. Univariate assessments employed chi-square, Fisher’s exact test, t-test, and Mann-Whitney U test. A logit model with L1 regularization, adjusted for age, gender, and ethnicity, pinpointed noteworthy non-genetic risk facto
Written by Carlos Ramirez
Published on Vol 6 Issue 1, 2026
The definitive contribution of surgical cytoreduction in stage IV gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) remains unclear, as corroborating data come largely from retrospective reviews that infrequently compare surgery with current systemic regimens. Drawing on a nationwide oncology registry, we compared overall survival (OS) with cytoreductive surgery versus systemic therapy alone. Eligible adults had a diagnosis of stage IV, well-differentiated GEP-NEN documented in the Nati
Written by Jinwoo Park
Published on Vol 6 Issue 1, 2026
Whether intensifying the radiotherapy dose for unresectable stage III NSCLC that is later managed with immunotherapy provides any advantage remains poorly understood. This analysis was designed to explore whether intermediate-dose escalation (IDE) yields a survival benefit in stage III NSCLC treated with definitive concurrent chemoradiation (dcCRT) and subsequent immunotherapy. The study extracted information from the National Cancer Database. All-cause mortality was evaluated through multivaria
Written by Sanjay Kulkarni
Published on Vol 6 Issue 1, 2026
Data are scarce on breast cancers (BC) identified in females with elevated genetic susceptibility, and comparisons are lacking between periods before and after they entered a sustained risk-governance scheme based on genetic risk stratification. We investigated clinical endpoints within the cohort enrolled in the Phare Grand Ouest (PGO) project. The PGO project enrolls BRCA1 and BRCA2 pathogenic variant (PV) carriers, as well as high-risk females without a BRCA PV, from eight clinical cancer gen
Written by Claire Dupont
Published on Vol 6 Issue 1, 2026
The advent of immune checkpoint inhibitors (ICIs) has fundamentally altered the treatment landscape for advanced hepatocellular carcinoma (HCC). Nevertheless, complete responses (CRs) are rarely observed, and their long-term outcomes remain incompletely delineated. This investigation explores the clinical consequences, pathologic associations, and most effective management protocols for HCC patients who achieve CR with ICI-based therapy. We performed a retrospective evaluation of 160 individuals
Written by Ahmed El-Kholy
Published on Vol 6 Issue 1, 2026
Colorectal cancer (CRC) constitutes a critical public health issue, compromising patients’ quality of life (QoL) and placing considerable strain on families and health services. To measure QoL and its associated factors among individuals with CRC in Qatar, and to determine the sociodemographic and clinical characteristics that shaped QoL during 2023. An analytical cross-sectional investigation was conducted between July and December 2023. Drawing from the National Center for Cancer Care and Rese
Written by Maria Gonzalez
Published on Vol 6 Issue 1, 2026
The goal of this work was to identify clinical indicators associated with bleeding episodes among individuals with acute leukemia receiving anticancer regimens and to develop and test a predictive nomogram based on those indicators. Encompassing 468 acute leukemia subjects, with acute promyelocytic leukemia diagnoses omitted, this retrospective cohort investigation drew on records from The Shanghai Fifth People’s Hospital and Nanyang Municipal Central Hospital covering January 2013 to December 2
Written by Bruno Martins
Published on Vol 6 Issue 1, 2026
Across the globe, cervical cancer persists as a frequent contributor to women’s deaths, with Africa bearing a disproportionate share. Nigerian statistics indicate that roughly 7093 women succumb to this illness every year. In response, the Society of Obstetrics and Gynecology of Nigeria (SOGON) formulated clinical practice guidelines to prevent cervical cancer. That said, the extent of these guidelines’ penetration into gynecological practice has not been systematically mapped. The present work
Established in 2019, Galaxy Publication stands as a global academic publishing house focused on advancing scholarly work across medicine, nursing, and health sciences. Through its network of peer-reviewed journals, the organization brings together original research and academic contributions from scholars around the world, creating a shared space for knowledge exchange and intellectual collaboration.
